The University of Arizona/Arizona Cancer Center (ACC) has been a continuously funded member institution of the Southwest Oncology Group (SWOG) since 1974. The current renewal application requests funding for years 37-41 to continue and expand institutional participation in the clincal research and treatment goals of SWOG via SWOG-and SWOG-endorsed efforts.
Specific aims and objectives remain as follows: 1. To continue to meet institutional scientific leadership and core service commitments within the Group, including: (a) protocol coordination (multiple studies);(b) disease and discipline committee administration;(c) reference and repository laboratory administration (including lymphoma, myeloma);(d) Group quality assurance and quality control. 2. To continue to promote the rapid integration of promising new research leads, including those developed at the ACC, into cooperative group testing to provide treatment options for a larger population of patients and improved patient care. 3. To continue to meet institutional clinical research commitments in the recruitment of appropriate patients for SWOG and SWOG-endorsed studies and all attendant commitments to longterm fllowup, quality assurance, quality control. 4. To continue and increase effforts to promote physician and patient awareness of and participation in SWOG and SWOG-endorsed clinical trials and outreach programs. 5. To continue efforts to understand factors affecting accrual paticularly those in special populations (eg, minority, elderly, financially disadvantaged) and to implement appropriate interventions where possible.
The ACC has a long history of scientific and administrative leadership in the SWOG and participation in national cooperative group treatment and prevention studies. A key element of its scientific contribution is institutional clinical and laboratory pilot work leading to national testing to establish new standards of care.
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Gustafson, Heather L; Yao, Song; Goldman, Bryan H et al. (2014) Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol 89:639-45|
|Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|Cook, James R; Goldman, Bryan; Tubbs, Raymond R et al. (2014) Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. Am J Surg Pathol 38:494-501|
|Sweetenham, J W; Goldman, B; LeBlanc, M L et al. (2010) Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol 21:1196-202|
|Swain, Sandra M; Jeong, Jong-Hyeon; Geyer Jr, Charles E et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053-65|
|Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47|
|Yao, Song; Barlow, William E; Albain, Kathy S et al. (2010) Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 16:6169-76|
|Markman, Maurie; Moon, James; Wilczynski, Sharon et al. (2010) Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 116:323-5|
Showing the most recent 10 out of 165 publications